Moffitt: FDA Approves Expanded Use of Immunotherapy Treatment for Lung Cancer Patients

Tuesday, February 27, 2018

The Food and Drug Administration announced the expanded approval of Imfinzi® (durvalumab), an immunotherapy treatment that is now available as a standard-of-care option for patients with stage III non-small cell lung cancer.

read more...